title: [The annual changes in antimicrobial susceptibility test results of Pseudomonas aeruginosa isolates from the Kinki district].
abstract: A study was conducted of the 1,225 Pseudomonas aeruginosa strains that were isolated at 20 medical institutions in the Kinki district between 2011 and 2013 to determine their antimicrobial susceptibility and to characterize the strains of multidrug-resistant Pseudomonas aeruginosa (MDRP) and the metallo-β-lactamase (MBL) -producing strains. The MIC50/MIC90 values (μg/mL) of the various antimicrobial agents were as follows: imipenem, 2/>8; meropenem, 1/>8; doripenem, 0.5/8; biapenem, 1/>8; tazobactam/piperacillin, 8/>64; piperacillin, 8/>64; sulbactam/cefoperazone, 8/64; cefepime, 4/16; cefozopran, 2/>16; aztreonam, 8/>16; amikacin, 4/16; levofloxacin, 1/>4; and ciprofloxacin, 0.25/>2. From the viewpoint of the annual changes in the susceptibility rates (according to the CLSI guidelines [M100-S22]), the susceptibility to tazobactam/piperacillin, piperacillin, cefepime, cefozopran and aztreonam decreased in 2013. On the other hand, two antimicrobial agents showed high susceptibility rates each year; amikacin (94.0-95.6%) showed the highest rate, followed by doripenem (80.3-82.6%). With the exception of amikacin, there were substantial inter-institutional differences in antimicrobial susceptibility. In comparison to the previous CLSI guidelines (M100-S21), the new CLSI guidelines (M100-S22) on the use of carbapenems and penicillins show that the MIC80 has been affected. The MDRP detection rates in 2011, 2012 and 2013 were 1.8% (8 strains), 1.8% (8 strains), and 2.8% (10 strains), respectively. The MBL detection rates were as follows: bla(VIM-2), 0.2% (1 strain) in 2011; bla(IMP-1), 0.9% (4 strains) in 2012, and 1.7% (6 strains, including bla(IMP-1) [3 strains], bla(IMP-2) [2 strains] and bla(VIM-2) [1 strain]) in 2013.
authors.forename: Saori
authors.initials: S
authors.lastname: Fukuda
authors.forename: Masaru
authors.initials: M
authors.lastname: Komatsu
authors.forename: Tatuya
authors.initials: T
authors.lastname: Nakamura
authors.forename: Takumi
authors.initials: T
authors.lastname: Jikimoto
authors.forename: Hisaaki
authors.initials: H
authors.lastname: Nishio
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Yamasaki
authors.forename: Kaori
authors.initials: K
authors.lastname: Satoh
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Toda
authors.forename: Tamaki
authors.initials: T
authors.lastname: Orita
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sueyoshi
authors.forename: Machiko
authors.initials: M
authors.lastname: Kita
authors.forename: Isao
authors.initials: I
authors.lastname: Nishi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Akagi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Higuchi
authors.forename: Tomomi
authors.initials: T
authors.lastname: Kofuku
authors.forename: Isako
authors.initials: I
authors.lastname: Nakai
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Ono
authors.forename: Kaneyuki
authors.initials: K
authors.lastname: Kida
authors.forename: Masanobu
authors.initials: M
authors.lastname: Ohama
authors.forename: Hideo
authors.initials: H
authors.lastname: Watari
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shimura
authors.forename: Makoto
authors.initials: M
authors.lastname: Niki
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Kuchibiro
authors.forename: Yasunao
authors.initials: Y
authors.lastname: Wada
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D007564:Japan; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification*
chemical_list: D000900:Anti-Bacterial Agents